Cipaglucosidase alfa: first approval
HA Blair - Drugs, 2023 - Springer
Cipaglucosidase alfa (Pombiliti™) is a recombinant human acid α-glucosidase (GAA)
product being developed by Amicus Therapeutics along with the enzyme stabilizer miglustat …
product being developed by Amicus Therapeutics along with the enzyme stabilizer miglustat …
[HTML][HTML] Cipaglucosidase Alfa-atga: Unveiling New Horizons in Pompe Disease Therapy
A Singh, R Debnath, A Saini, K Seni, A Sharma… - Health Sciences …, 2024 - Elsevier
Pompe disease is a lysosomal storage disease characterized by impaired glycogen
breakdown due to an acid α-glucosidase (GAA) enzyme deficiency. Without therapy …
breakdown due to an acid α-glucosidase (GAA) enzyme deficiency. Without therapy …